85 results
The objective of this study is to investigate the safety and effectiveness of different combinations of cancer immunotherapies compared to either Nivolumab or Ipilimumab, as determined by comparing the Overall Response Rate, at 24 weeks in patients…
• To evaluate the efficacy of treatment• To evaluate the safety of treatment
Objectives of the studyPrimary ObjectiveTo compare recurrence-free survival (RFS)(based on BICR assessment) of nivolumab versus placebo in all randomized participants.Secondary Objectives• To compare overall survival (OS) of nivolumab versus placebo…
The study aims to demonstrate that treatment with nivolumab combined with ipilimumab will improve efficacy in cisplatin-ineligible participants with previously untreated unresectable or metastatic UC and also treatment with nivolumab combined with…
Primary Objective:All lines1) To compare the BICR-assessed PFS of participants with centrally confirmed dMMR/MSI-H mCRC and randomized to nivolumab plus ipilimumab combination therapy arm or nivolumab monotherapy arm1L1) To compare the BICR-assessed…